



# ADVANCES IN LIPOBIOLOGY

Editor: RICHARD W. GROSS

*Department of Bioorganic Chemistry  
and Molecular Pharmacology  
Washington University School of Medicine  
St. Louis, Missouri*

---

VOLUME 1 • 1996



JAI PRESS INC.

Greenwich, Connecticut

London, England

Copyright © 1996 by JAI PRESS INC.  
55 Old Post Road, No. 2  
Greenwich, Connecticut 06836

JAI PRESS LTD.  
38 Tavistock Street  
Covent Garden  
London, WC2E 7PB  
England

All rights reserved. No part of this publication may be reproduced, stored on a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, filming, recording, or otherwise, without prior permission in writing from the publisher.

ISBN: 1-55938-635-5

Manufactured in the United States of America

ADVANCES IN  
LIPOBIOLOGY

Volume 1 • 1996

EDITED BY RICHARD W. GROSS

*Department of Bioorganic Chemistry*

*and Molecular Pharmacology*

*Washington University School of Medicine*

*St. Louis, Missouri*

---

VOLUME 1 • 1996



JAI PRESS INC.

Greenwich, Connecticut

London, England

## LIST OF CONTRIBUTORS

<i>Rosa J. Buxeda</i>	Department of Food Science Rutgers University New Brunswick, New Jersey
<i>George M. Carman</i>	Department of Food Science Rutgers University New Brunswick, New Jersey
<i>Rosalind A. Coleman</i>	Department of Pediatrics Duke University Medical Center Durham, North Carolina
<i>Rosemary Cornell</i>	Department of Chemistry Simon Fraser University Burnaby, British Columbia, Canada
<i>David A. Ford</i>	Department of Internal Medicine Washington University School of Medicine St. Louis, Missouri
<i>Rene A. Frenkel</i>	Department of Biochemistry University of Texas Southwestern Medical School Dallas, Texas
<i>John A. Glomset</i>	Howard Hughes Medical Institute Research Laboratories University of Washington Seattle, Washington
<i>Richard W. Gross</i>	Department of Bioorganic Chemistry and Molecular Pharmacology Washington University School of Medicine St. Louis, Missouri

<i>Tada-atsu Imaizumi</i>	Department of Internal Medicine and Biochemistry University of Utah School of Medicine Salt Lake City, Utah
<i>Suzanne Jackowski</i>	Department of Biochemistry St. Jude Children's Research Hospital Memphis, Tennessee
<i>John M. Johnston</i>	Department of Biochemistry University of Texas Southwestern Medical School Dallas, Texas
<i>James B. Lefkowitz</i>	Department of Medicine Washington University School of Medicine St. Louis, Missouri
<i>Michelle Lennartz</i>	Departments of Physiology and Cell Biology Albany Medical College Albany, New York
<i>Christina C. Leslie</i>	Department of Pediatrics National Jewish Center Denver, Colorado
<i>Dennis C. Liotta</i>	Department of Chemistry Emory University Atlanta, Georgia
<i>Thomas M. McIntyre</i>	Department of Internal Medicine and Biochemistry University of Utah School of Medicine Salt Lake City, Utah
<i>Alfred H. Merrill, Jr.</i>	Department of Biochemistry Emory University School of Medicine Rollins Research Center Atlanta, Georgia
<i>Hisashi Narhara</i>	Department of Biochemistry University of Texas Southwestern Medical School Dallas, Texas

- |                               |   |
|-------------------------------|---|
| <i>Joseph T. Nickels, Jr.</i> | Department of Food Science<br>Rutgers University<br>New Brunswick, New Jersey                       |
| <i>Norman S. Radin</i>        | Nephrology Division<br>University of Michigan Medical Center<br>Ann Arbor, Michigan                 |
| <i>Sasanka Ramanadham</i>     | Washington University School of<br>Medicine<br>St. Louis, Missouri                                  |
| <i>Ronald T. Riley</i>        | Toxicology and Mycotoxins Research<br>Unit/USDA-ARS<br>Athens, Georgia                              |
| <i>Charles O. Rock</i>        | Department of Biochemistry<br>St. Jude Children's Research Hospital<br>Memphis, Tennessee           |
| <i>Richard Schulz</i>         | Departments of Pediatrics and<br>Pharmacology<br>University of Alberta<br>Edmonton, Alberta, Canada |
| <i>Diana M. Stafforini</i>    | Department of Internal Medicine<br>University of Utah School of Medicine<br>Salt Lake City, Utah    |
| <i>Pamela J. Trotter</i>      | Department of Medicine<br>National Jewish Center<br>Denver, Colorado                                |
| <i>John Turk</i>              | Washington University School of<br>Medicine<br>St. Louis, Missouri                                  |
| <i>Dennis Voelker</i>         | Department of Medicine<br>National Jewish Center<br>Denver, Colorado                                |
| <i>Robert A. Wolf</i>         | Department of Medicine<br>Washington University School of<br>Medicine<br>St. Louis, Missouri        |

*Yoshiji Yamada*

Department of Internal Medicine and  
Biochemistry  
University of Utah School of Medicine  
Salt Lake City, Utah

*Steven H. Zeisel*

Department of Pediatrics  
Duke University Medical Center  
Durham, North Carolina

*Guy A. Zimmerman*

Department of Internal Medicine and  
Biochemistry  
University of Utah School of Medicine  
Salt Lake City, Utah



## PREFACE

---

The last decade has witnessed explosive advances in our understanding of the role of membranes, lipid second messengers, and lipid metabolism in the molecular mechanisms regulating cell growth, differentiation, and ligand-regulated cellular activation. In large part, these insights have been facilitated by the exploitation of new methodologies including genetic engineering (molecular biology), analytical instrumentation (biophysical chemistry), and computer technology (molecular modeling and drug design). While the application of these methodologies to their parent disciplines has resulted in the easily detectable emergence of new concepts and principles, their central role in the growth of lipobiology has been less evident, especially to students embarking on new scientific careers. Accordingly, it was envisaged that a series of cohesive didactic discussions identifying rapidly-evolving scientific arenas in lipobiology would serve to illustrate the dynamic nature of the field and encourage students to participate in this rapidly-evolving discipline focused at the interface of lipid chemistry and biology. This series was created to provide a forum for leading scientists in the field of lipobiology to: (1) broadly interpret the potential significance of recent findings in the area of lipid structure and function, (2) identify what does (and what does not) constitute "proof of concept," and (3) provide a critical foundation for evaluation of experimental results and strategies in these rapidly evolving arenas. While some historical information has been presented, the purpose of this series is to provide a medium for discussion of emerging concepts by experts in the field.

It is my sincere hope that the extensive efforts by the contributors in this edition to illustrate the recent growth in the scope of investigations in lipid research will be recognized by the next generation of scientists and encourage them to fulfill the promise of our conjoint expectations.

Richard W. Gross  
*Editor*

# CONTENTS

LIST OF CONTRIBUTORS	ix
PREFACE	
<i>Richard W. Gross</i>	xiii
REGULATION OF MAMMALIAN CTP: PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	
<i>Rosemary B. Cornell</i>	1
INCORPORATION AND TURNOVER OF FATTY ACIDS IN <i>ESCHERICHIA COLI</i> MEMBRANE PHOSPHOLIPIDS	
<i>Charles O. Rock and Suzanne Jackowski</i>	39
A BRANCHED METABOLIC PATHWAY IN ANIMAL CELLS CONVERTS 2-MONOACYLGLYCEROL INTO <i>sn</i> -1-STEAROYL-2-ARACHIDONOYL PHOSPHATIDYLINOSITOL AND OTHER PHOSPHOGLYCERIDES	
<i>John A. Glomset</i>	61
PROPERTIES AND REGULATION OF MAMMALIAN NONPANCREATIC PHOSPHOLIPASE A <sub>2</sub> ENZYMES	
<i>Christina C. Leslie</i>	101
THE FATE OF PLATELET-ACTIVATING FACTOR: PAF ACETYLHYDROLASES FROM PLASMA AND TISSUES	
<i>Tada-atsu Imaizumi, Diana M. Stafforini, Yoshiji Yamada, Guy A. Zimmerman, Thomas M. McIntyre, and Stephen M. Prescott</i>	141
BIOSYNTHESIS OF PLASMALOGENS IN MAMMALIAN CELLS AND THEIR ACCELERATED CATABOLISM DURING CELLULAR ACTIVATION	
<i>David A. Ford and Richard W. Gross</i>	163

PLASMALOGENS, NITROXIDE FREE RADICALS, AND ISCHEMIA-REPERFUSION INJURY IN THE HEART <i>Richard Schulz</i>	193
PHOSPHOLIPID HYDROLYSIS IN PANCREATIC ISLET BETA CELLS AND THE REGULATION OF INSULIN SECRETION <i>John Turk, Richard W. Gross, and Sasanka Ramanadham</i>	215
THE ROLE OF PAF IN REPRODUCTIVE BIOLOGY <i>Hisashi Narahara, Rene A. Frenkel, and John M. Johnston</i>	241
SPHINGOLIPIDS AS REGULATORS OF CELLULAR GROWTH, DIFFERENTIATION, and BEHAVIOR <i>Alfred H. Merrill, Jr., Dennis C. Liotta, and Ronald T. Riley</i>	273
PHOSPHATIDYLSERINE DYNAMICS AND MEMBRANE BIOGENESIS <i>Pamela J. Trotter and Dennis R. Voelker</i>	299
DIACYLGLYCEROL METABOLISM IN CELLULAR MEMBRANES <i>Rosalind A. Coleman and Steven H. Zeisel</i>	337
PHOSPHATIDYLINOSITOL 4-KINASES IN <i>SACCHAROMYCES CEREVISIAE</i> <i>George M. Carman, Rosa J. Buxeda, and Joseph T. Nickels, Jr.</i>	367
PHOSPHOINOSITIDE METABOLISM IN MYOCARDIAL TISSUE <i>Robert A. Wolf</i>	387
ROLE OF ARACHIDONATE IN MONOCYTE/MACROPHAGE FUNCTION <i>Michelle R. Lennartz and James B. Lefkowitz</i>	429
INDEX	463

# REGULATION OF MAMMALIAN CTP: PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE

Rosemary B. Cornell

---

I. ROLE OF CT IN PC SYNTHESIS . . . . .	2
A. CT Catalyzes a Rate-Limiting Reaction . . . . .	2
B. Evidence for Other Rate-Limiting Steps . . . . .	4
II. ROLE OF CT IN CONTROL OF LIPID SECOND MESSENGER CONCENTRATIONS . . . . .	4
A. CT Controls the PC Metabolic Cycle . . . . .	4
B. CT Attenuates the Agonist-Induced DAG Signal . . . . .	5
III. CT IS A REGULATED ENZYME . . . . .	5
A. Posttranslational Regulation . . . . .	6
B. Pretranslational Regulation . . . . .	6
IV. INTRACELLULAR DISTRIBUTION AND TRANSLOCATION BETWEEN SITES . . . . .	7
A. Distribution of CT as Assessed by Cell Fractionation . . . . .	7
B. Activity of the Cytosolic and Membrane Forms . . . . .	7
C. Interconversion of Soluble and Membrane-Bound CT . . . . .	8
D. Physiological Relevance of the Translocation Model . . . . .	10
E. Identity of the Membrane to Which CT Binds . . . . .	11
F. Two Forms of Soluble CT . . . . .	12
G. Nontranslocatable Membrane-Bound CT . . . . .	14

---

Advances in Lipobiology

Volume 1, pages 1-38.

Copyright © 1996 by JAI Press Inc.

All rights of reproduction in any form reserved.

ISBN: 1-55938-635-5


V.	REGULATION OF CT ACTIVITY BY LIPIDS <i>IN VITRO</i> . . . . .	14
A.	Classification of Lipid Modulators . . . . .	15
B.	Critical Features of the Activating Membrane . . . . .	16
VI.	REGULATION OF CT ACTIVITY BY PHOSPHORYLATION . . . . .	17
A.	Effects of Manipulation of Phosphorylation Conditions . . . . .	17
B.	cAMP and Phorbol Esters do not Affect CT Phosphorylation . . . . .	18
C.	CT is a Phosphoenzyme . . . . .	19
D.	Effects of Okadaic Acid on CT . . . . .	19
E.	Effects of Cholecystokinin . . . . .	20
F.	Effects of Phospholipase C . . . . .	20
G.	Effects of Oleic Acid . . . . .	21
VII.	STRUCTURE OF MAMMALIAN CT . . . . .	21
A.	Molecular Mass and Subunit Structure . . . . .	21
B.	Amino Acid Sequence and Sequence Homologies . . . . .	22
C.	Phosphorylation Sites . . . . .	23
D.	Secondary and Tertiary Structural Predictions . . . . .	24
E.	Membrane-Binding Domain . . . . .	24
F.	Dimerization Domain . . . . .	26
G.	Model of CT Interaction With Membranes . . . . .	26
VIII.	MECHANISM OF THE REGULATION OF ACTIVITY <i>IN VIVO</i> . . . . .	27
A.	Regulation Induced Solely by Changes in the Lipid Composition . . . . .	27
B.	Regulation Induced Solely by Changes in Phosphorylation . . . . .	28
C.	Regulation Involving Changes in Both Lipid Composition and Phosphorylation . . . . .	29
D.	Interrelationship of the Various CT Conformations . . . . .	30
IX.	FUTURE DIRECTIONS . . . . .	31
	ACKNOWLEDGMENTS . . . . .	32
	REFERENCES . . . . .	32

## I. ROLE OF CT IN PC SYNTHESIS

CTP:phosphocholine cytidyltransferase (EC. 2.7.7.15, CT) is an important regulatory enzyme in phosphatidylcholine (PC)<sup>1</sup> metabolism. It catalyzes the transfer of a cytidyl group from CTP to phosphocholine to form CDPcholine, the head group carrier molecule. CDPcholine is subsequently attacked by diacylglycerol (DAG), releasing CMP and forming PC. This pathway for forming PC is the dominant pathway in all animal cells (see Figure 1).

### A. CT Catalyzes a Rate-Limiting Reaction

The ratio of the metabolite concentrations in a pathway can indicate the slowest step. The pool sizes of the choline containing metabolites in the CDPcholine pathway have been analyzed in liver (Sundler et al., 1972), lung (Post et al., 1984), skeletal muscle cells (Sleight and Kent, 1980), HeLa cells (Vance et al., 1980; Wang



**Figure 1.** CT is activated by at least three products of PC catabolism. The evidence for activation by PA is based on *in vitro* effects only.

et al., 1993a), and several other cell lines (Cornell and Goldfine, 1983; Sleight and Kent, 1983a; Tessner et al., 1991). The ratio of phosphocholine to CDPcholine ranges from 10 (Post et al., 1984) to 150 (Wang et al., 1993a). This indicates a bottle-neck at the CT catalyzed reaction. Secondly,  $^3\text{H}$ -choline pulse-chase studies have directly indicated that the conversion of phosphocholine to CDP-choline is the slowest step in the pathway (Vance et al., 1980; Pritchard and Vance, 1981; Post et al., 1982; Cornell and Goldfine, 1983). In addition there are several examples of changes in the rate of PC synthesis which correlate with changes in the relative ratio of phosphocholine:CDPcholine or changes in the turnover rate of phosphocholine. For example, fatty acid stimulation of PC synthesis in HeLa cells caused a decrease in phosphocholine and an increase in CDP-choline such that the ratio decreased from 150 to 12 (Wang et al., 1993a). Phospholipase C (PLC) treatment of chick myoblasts stimulated PC synthesis and caused a 60% decrease in phosphocholine and a 2.5-fold increase in CDPcholine (Sleight and Kent, 1980). PC synthesis was elevated in lung from prematurely born rats due to activation of CT. The phosphocholine pool size decreased at least fourfold (Possmayer et al., 1981; Weinhold et al., 1982). Inhibitors of cholesterol synthesis inhibited PC synthesis in  $L_6$  myoblasts and led to an increase in the ratio of phosphocholine:CDPcholine, and an increase in the turnover of phosphocholine (Cornell and Goldfine, 1983). Poliovirus infection (Vance et al., 1980) or phorbol ester (Paddon and Vance, 1980) stimulated PC synthesis twofold in HeLa cells and increased the phosphocholine turnover rate twofold.

## B. Evidence for Other Rate-Limiting Steps

The reaction catalyzed by CT may not be the rate-limiting step under every condition. The concentration of DAG, the substrate for the terminal reaction, can be the rate-limiting factor. PC synthesis was inhibited when hepatocytes were treated with cAMP analogues, however there was no effect on CT activity. Rather, the DAG content of cellular membranes decreased probably due to inhibition of fatty acid production (Jamil et al., 1992). Replenishment of the DAG restored the PC synthesis rate in a direct concentration-dependent manner. Secondly, PC synthesis was stimulated only threefold when CT was over-expressed in COS cells, although the amount of the active form of CT increased nearly 20-fold. The CDPcholine concentration increased 12-fold, indicative of a bottleneck at the terminal step. Increasing the supply of DAG stimulated PC synthesis fourfold (Walkey et al., 1994).

The choline kinase catalyzed step can also be rate limiting. This conclusion is based on a change in the specific activity of choline kinase that correlates with the change in the PC synthesis rate (e.g., Warden and Friedkin, 1985), or a change in the ratio of choline:phosphocholine in a direction opposite to that of choline flux. Regulation of PC synthesis by choline kinase or the supply of choline has been recently reviewed (Tijburg et al., 1989; Kent et al., 1991).

## II. ROLE OF CT IN CONTROL OF LIPID SECOND MESSENGER CONCENTRATIONS

### A. CT Controls the PC Metabolic Cycle

PC is the source of DAG production via phospholipase D and phosphatidic acid phosphatase in response to bombesin, epinephrine, vasopressin, cholecystokinin, and other agonists (Billah and Anthes, 1990). In these pathways, phosphatidylinositol bisphosphate- ( $\text{PIP}_2$ ) specific PLC generates the first wave of DAG production, followed by more sustained production of DAG via the hydrolysis of PC. PC is also the immediate precursor to DAG via PC-specific PLC in response to interleukins 1 or 3, tumor necrosis factor  $\alpha$ , interferon- $\alpha$ , and colony stimulating factor-1 (Liscovitch, 1992). In these latter signal transduction pathways no  $\text{PIP}_2$  hydrolysis occurs; rather PC seems to be the sole generator of DAG. PC is also a source of arachidonic acid via  $\text{PLA}_2$ . Protein kinase C (PKC) appears to be both required for and activated by the sustained production of second messengers from PC. For the long-term effects of PKC activity, a prolonged production of DAG would be needed. If enhanced PC hydrolysis were to continue for several hours without any stimulation of PC synthesis this would likely lead to a fatal reduction in membrane PC content. However, in every system investigated the stimulation of PC catabolism results in an acceleration of synthesis (e.g., Sleight and Kent, 1980; Guy and Murray, 1982; Lacal, 1990). This and other data (Terce et al., 1991; Tijburg et al.,



1991; Walkey et al., 1994) provide strong evidence for a tightly controlled PC metabolic cycle in which synthesis and degradation are closely coupled (Pelech and Vance, 1989; Tronchère et al., 1994). Stimulation of PC synthesis usually involves activation of CT. Three of the products of degradation of PC are known activators of CT: fatty acids, DAG, and PA (Figure 1). In this way CT plays a regulatory role in the maintenance of PC homeostasis in cells activated by a wide variety of agonists.

### B. CT Attenuates the Agonist-Induced DAG Signal

CT may also be involved in attenuation of the DAG signal. DAG can be metabolized by lipase to produce fatty acids, by kinase to produce PA, by acyltransferase to produce triacylglycerol, or by phosphotransferases to produce PE or PC. The importance of the phosphotransferase pathway in the metabolism of DAG has been illuminated recently. DAG accumulates in liver of rats in which PC synthesis has been inhibited by deprivation of choline (Blusztajn and Zeisel, 1989). Similarly, in pancreatic acini, inhibition of PC synthesis by cholecystokinin resulted in increased DAG levels, suggesting that the major clearance route for DAG in these cells is via incorporation into PC (Matozaki et al., 1991). Using labeled long-chain DAG species introduced into 3T3 fibroblasts by liposome fusion, Florin-Christensen et al. (1992) found that the predominant metabolic destiny of [1-18:0, 2-20:4]-DAG was PC. The DAGs appeared to be incorporated intact into PC, that is, without first being degraded to the free fatty acid. Increases in [DAG] stimulate DAG kinase or lipase by substrate level control, whereas increases in [DAG] may stimulate the synthesis of PC at the substrate level and/or by allosteric activation of CT. DAG has been shown to activate CT both *in vitro* (Cornell and Vance, 1987a,b; Cornell, 1991b) and *in vivo* (Rosenberg et al., 1987; Kolesnick and Hemer, 1990; Slack et al., 1991). Thus increases in [DAG] would accelerate the formation of CDPcholine, the rate-limiting substrate in the pathway, and thus the rate of the CPT-catalyzed reaction, which converts DAG to PC.

## III. CT IS A REGULATED ENZYME

The activity of CT is regulated by many factors. The addition to cultured cells of phorbol esters (Pelech et al., 1984a), phospholipases (Sleight and Kent, 1980), fatty acids (Pelech et al., 1984b), diacylglycerol (Utal et al., 1991), calcium ionophore (Sanghera and Vance, 1989a), and CSF-1 (Tessner et al., 1991) all lead to stimulation of CT activity. Glucocorticoid or estrogen treatment also activates CT in developing lung (Possmayer et al., 1981; Chu and Rooney, 1985; Rooney et al., 1990; Xu et al., 1990). Treatment of cells with okadaic acid (Hatch et al., 1992), cholesterol synthesis inhibitors (Cornell and Goldfine, 1983), cholecystokinin (Matozaki et al., 1991), alkyl phosphocholine (Geilen et al., 1992), and transfection with H-ras (Teegarden et al., 1990) inhibit CT activity. Are these agents acting via